BioSpace News Archive

nference will present research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago.

Nyxoah SA announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, in which 5,374,755 shares of its ordinary shares were sold at an offering price of $9.25 per share, before underwriting discounts and commissions.

AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of risankizumab for the treatment of adults with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy.

Mesa Laboratories, Inc. will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 as previously communicated.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1, 2024.

IDEAYA Biosciences, Inc. announced that, on May 30, 2024, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 49,000 shares of the Company’s common stock to two newly hired employees.

atai Life Sciences today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.

Adaptive Biotechnologies Corporation announced that its next-generation sequencing (NGS)-based clonoSEQ ® test for measurable residual disease (MRD) assessment will be included in several oral and poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.

Lobe Sciences Ltd. today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors.